Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osimertinib companion diagnostic - Guardant Health/AstraZeneca

Next Previous
Drug Profile

Osimertinib companion diagnostic - Guardant Health/AstraZeneca

Alternative Names: Osimertinib Guardant360® CDx companion diagnostic

Latest Information Update: 16 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guardant Health
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 16 Oct 2023 Discontinued - Phase-III for Non-small cell lung cancer (Diagnosis) in Mexico, Netherlands, Hong Kong, Sweden, Portugal, Saudi Arabia, Malaysia, China, Israel, Brazil, Japan, South Korea, Philippines, Russia, Switzerland, Poland, Bulgaria, Czech Republic, Belgium, Spain, Romania, Germany, France, Italy, Taiwan, Hungary, Thailand, Turkey, Ukraine, Australia, Vietnam, United Kingdom, Canada (unspecified route)
  • 18 Jan 2021 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route) in January 2021
  • 07 Aug 2020 Registered for Non-small cell lung cancer (Diagnosis, Metastatic disease) in USA (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top